Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 6, 2009, Pages 1044-1050

  Vandooren, B ^a,b   Cantaert, T ^a   Van Lierop, M J ^c   Bos, E ^c   De Rycke, L ^a   Veys, E M ^b   De Keyser, F ^b   Bresnihan, B ^d   Luyten, F P ^e   Verdonk, P C ^b   Tak, P P ^a   Boots, A H ^c   Baeten, D ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c NV Organon ^*  (Netherlands)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; ALGINIC ACID; BIOLOGICAL MARKER; COLLAGEN TYPE 2; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; INTERLEUKIN 1BETA; MELANOMA INHIBITORY ACTIVITY PROTEIN; MESSENGER RNA; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOSYNTHESIS; CARTILAGE ANABOLISM; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE MATRIX; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; JOINT; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVIAL FLUID; SYNOVITIS; TISSUE DISTRIBUTION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELLS, CULTURED; CHONDROCYTES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPONDYLARTHRITIS; STATISTICS, NONPARAMETRIC; STIMULATION, CHEMICAL; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67449133538     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.085837     Document Type: Article

References (31)

1. Karouzakis E, Neidhart M, Gay RE, Gay S. Molecular and cellular basis of rheumatoid joint destruction. Immunol Lett 2006;106:8-13. (Pubitemid 44093056)
2. Sumer EU, Schaller S, Sondergaard BC, Tanko LB, Qvist P. Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers 2006;11:485-506. (Pubitemid 44614822)
3. Garnero P, Landewe R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-2856 (Pubitemid 35315875)
4. Landewe R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1390-1399
5. Goldring MB. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 2006;20:1003-1025 (Pubitemid 44382386)
6. Dietz UH, Sandell LJ. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem 1996;271:3311-3316 (Pubitemid 26055637)
7. Bosserhoff AK, Kondo S, Moser M, Dietz UH, Copeland NG, Gilbert DJ, et al. Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn 1997;208:516-525 (Pubitemid 27152843)
8. Sanyal A, Clemens V, Fitzsimmons JS, Reinholz GG, Sarkar G, Mukherjee N, et al. Induction of CD-RAP mRNA during periosteal chondrogenesis. J Orthop Res 2003;21:296-304. (Pubitemid 36322550)
9. Okazaki K, Li J, Yu H, Fukui N, Sandell LJ. CCAAT/enhancer-binding proteins beta and delta mediate the repression of gene transcription of cartilage-derived retinoic acid-sensitive protein induced by interleukin-1 beta. J Biol Chem 2002;277:31526-31533 (Pubitemid 34968954)
10. Imamura T, Imamura C, McAlinden A, Davies SR, Iwamoto Y, Sandell LJ. A novel tumor necrosis factor alpha-responsive CCAAT/enhancer binding protein site regulates expression of the cartilage-derived retinoic acid-sensitive protein gene in cartilage. Arthritis Rheum 2008;58:1366-1376 (Pubitemid 351705926)
11. Tscheudschilsuren G, Bosserhoff AK, Schlegel J, Vollmer D, Anton A, Alt V, et al. Regulation of mesenchymal stem cell and chondrocyte differentiation by MIA. Exp Cell Res 2006;312:63-72. (Pubitemid 41668592)
12. Moser M, Bosserhoff AK, Hunziker EB, Sandell L, Fassler R, Buettner R. Ultrastructural cartilage abnormalities in MIA/CD-RAP-deficient mice. Mol Cell Biol 2002;22:1438-1445 (Pubitemid 34150780)
13. Muller-Ladner U, Bosserhoff AK, Dreher K, Hein R, Neidhart M, Gay S, et al. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology 1999;38:148-154 (Pubitemid 29507236)
14. Neidhart M, Muller-Ladner U, Frey W, Bosserhoff AK, Colombani PC, Frey-Rindova P, iet al. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cartilage 2000;8:222-229
15. Lemare F, Steimberg N, Le Griel C, Demignot S, Adolphe M. Dedifferentiated chondrocytes cultured in alginate beads: restoration of the differentiated phenotype and of the metabolic responses to interleukin-1β. Cell Physiol 1998;176:303-313 (Pubitemid 28319713)
16. van Lierop MJC, den Hoed L, Houbiers J, Vencovsky J, Ruzickova S, Krystufkova O, et al. Endogenous HLA-DR restricted presentation of the cartilage antigens, MIA and HC gp-39, in the inflamed rheumatoid joint. Arthritis Rheum 2007;56:2150-2159
17. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156. (Pubitemid 17064313)
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
19. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218-1227
20. Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004;50:2942-2953 (Pubitemid 39209533)
21. Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004;31:1103-1111 (Pubitemid 38715885)
22. Baeten D, Demetter P, Cuvelier C, Van Den Bosch F, Kruithof E, Van Damme N, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000;59:945-953
23. Luyten FP, Lories RJ, Verschueren P, de Vlam K, Westhovens R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol 2006;20:829-848 (Pubitemid 44356463)
24. Smeets RL, Veenbergen S, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB, et al. A novel role for suppressor of cytokine signaling 3 in cartilage destruction via induction of chondrocyte desensitization toward insulin-like growth factor. Arthritis Rheum 2006;54:1518-1528
25. Saito S, Kondo S, Mishima S, Ishiguro N, Hasegawa Y, Sandell LJ, et al. Analysis of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid from patients with osteoarthritis and rheumatoid arthritis. J Bone Joint Surg Br 2002;84:1066-1069
26. Schmidt-Rohlfing B, Schneider U, Thomsen M, Bosserhoff AK. Correlation of a novel matrix protein with the degree of cartilage degradation. Rheumatol Int 2002;22:165-169 (Pubitemid 35002209)
27. Månsson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-1077
28. Rousseau JC, Zhu Y, Miossec P, Vignon E, Sandell LJ, Garnero P, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004;12:440-447 (Pubitemid 38696944)
29. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003;48:3085-3095 (Pubitemid 37409319)
30. Briot K, Roux C, Gossec L, Charni N, Kolta S, Dougados M, et al. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy. J Rheumatol 2008;35:310-314 (Pubitemid 351281153)
31. van der Heijde D, Landewe R, Boonen A, Einstein S, Herborn G, Rau R, et al. Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. Arthritis Res Ther 2007;9:R6. (Pubitemid 47244909)